Furthermore, the therapeutic mainstay for patients with CVID, namely immunoglobulin replacement, seems not to affect the levels of CXCL13, adding to the clinical usefulness and reliability of measuring CXCL13 [74]. The gene discussed is CXCL13; the disease is common variable immunodeficiency.